Study of AGN1 LOEP to Prevent Secondary Hip Fractures

  • STATUS
    Recruiting
  • End date
    Apr 1, 2029
  • participants needed
    2400
  • sponsor
    AgNovos Healthcare, LLC
Updated on 4 October 2022
hip fracture
fragility fracture

Summary

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Description

This is an event driven, randomized, controlled, prospective, single blinded, multi-national study.

This study is designed to demonstrate that the AGN1 LOEP treatment can reduce the incidence of secondary hip fractures in subjects presenting with an index hip fracture and undergoing hip fracture repair surgery. Subjects presenting with an index fragility hip fracture who will undergo hip fracture repair will be enrolled. Subjects will be randomized 1:1 into the following two study groups:

  1. Treated Group - receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
  2. Control Group - receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip

AGN1 LOEP is an elective procedure that will be performed immediately following hip fracture repair.

Subjects will be followed through scheduled visits conducted at 6 weeks, 6 months, and every 6 months thereafter for a minimum of 5 years.

Details
Condition Osteoporosis, Osteopenia, fragility fracture, HIP FRACTURE, hip fractures, broken hip
Treatment AGN1 LOEP treatment
Clinical Study IdentifierNCT04796350
SponsorAgNovos Healthcare, LLC
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age
Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip
Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review)
Documented falls assessment indicating subject is at moderate or high risk of falls
Falls history (2 or more falls in the previous 12 months)
History of vertigo, dizziness, or postural hypotension
Documented T-score < -2.5 at the hip
Taking more than 3 daily prescription medications
Visual impairment as confirmed by one of the following
Subject reports difficulty seeing
Lack of depth perception or vision loss in one eye
Macular degeneration
Cataracts
Prior non-hip fragility fracture
Cognitive frailty as assessed by SPMSQ (mild or moderate cognitive impairment) or delirium
Parkinson's disease stage 3 or 4
-year hip fracture probability >15% using the FRAX Fracture Risk Assessment Tool of the clinical site country
Subject is expected to be ambulatory after the hip fracture repair procedure
Informed consent is provided by the subject or the subject's LAR
The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented

Exclusion Criteria

Subject hospital admission is > 24 hours from the time of the index hip fracture
Subject was dependent on the use of a wheelchair or was bedridden prior to the index hip fracture
Subject is currently enrolled in another clinical study
Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture
Subject has one or more new fractures in addition to the index hip fracture at admission
Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment
Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side
Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures
Subject is at ASA Class IV, V, or VI
Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia)
Subject has a history of Pott's disease
Subject has a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for 5 years
Subject has chronic cardiac insufficiency or severe cardiovascular disease as assessed by a subject or LAR interview to be NYHA Class III or IV or has an implanted pacemaker
Subject has a history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, unstable angina, pulmonary embolus, deep vein thrombosis, ventricular tachycardia, or atrial fibrillation) in the last 3 months
Subject is on oral or parenteral immuno-suppressive drugs
Subject has uncontrolled diabetes mellitus
Subject has Hb 10 g/dL at admission
Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) 30 mL/min
Subject has albumin corrected serum calcium levels outside the normal laboratory range or has a pre-existing calcium metabolism disorder (e.g. hypercalcemia)
Subject has a Parker Mobility Score 5
Subject has severe cognitive impairment as assessed by SPMSQ
Subject has known allergies to calcium-based bone void fillers
In the judgement of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues)
Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note